A research team hailing from Leiden University has engineered an experimental antibiotic, designated EVG7, which demonstrates potent efficacy against the virulent gut bacterium Clostridioides difficile, even in minute concentrations. Furthermore, this compound substantially mitigates the likelihood of secondary infections, a primary hurdle in addressing this particular affliction. Their findings were detailed in the scientific periodical Nature Communications (NatCom).
Clostridioides difficile remains a leading cause of severe intestinal ailments, disproportionately affecting the elderly and individuals with compromised immune systems. The bacterium secretes toxins that induce acute diarrhea and intestinal inflammation. While prescribed antibiotics are the conventional treatment strategy, approximately one-quarter of affected individuals experience a recurrence of the infection weeks following therapy completion.
The novel compound, EVG7, was developed within the laboratory overseen by Professor Nathaniel Martin at the Institute of Biology, part of Leiden University. It represents an optimized and more targeted iteration of the widely employed antibiotic, vancomycin.
The compound’s efficacy was evaluated using laboratory mice models. Due to EVG7’s inherent potency, the researchers were able to administer significantly lower quantities compared to standard antibiotic regimens. It was observed that these minimal doses proved maximally beneficial; the laboratory animals exhibited a far less frequent recurrence of the infection when treated this way.
Alternative treatment protocols yielded inferior outcomes. Specifically, reduced dosages of vancomycin failed to prevent relapses, and even higher concentrations of vancomycin demonstrated less overall effectiveness.
To pinpoint the rationale behind this distinct result, scientists scrutinized the intestinal microbiome of the test subjects. The data indicated that administering a small amount of EVG7 preserved a significantly greater population of beneficial microorganisms, notably those belonging to the Lachnospiraceae family.
Numerous antibiotics decimate the majority of the gut microflora, including beneficial species. Conversely, EVG7 appears to cause minimal disruption to the microbiome. It is these surviving native microbes that obstruct lingering C. difficile spores from reactivating into a full-blown infection.
Another critical concern with antibiotic use is the escalation of bacterial resistance. EVG7, even at low concentrations, completely eliminates the pathogen, thereby minimizing the probability of resistance developing.
The drug still requires further safety evaluations. Should the toxicological assessments prove favorable, human clinical trials could commence in the near future.
About the Author
